Oragenics Regains NYSE Compliance After Public Offering
I'm PortAI, I can summarize articles.
Oragenics (OGEN) has regained compliance with NYSE American listing standards after a $16.5 million public offering in July 2025. The company settled a $700,000 dispute with Ladenburg Thalmann & Co. related to an investment banking agreement. Despite this, Spark's AI Analyst rates OGEN as Underperform due to significant financial distress, negative equity, and cash flow issues, leading to a low performance score. Oragenics is advancing its lead candidate, ONP-002, for treating traumatic brain injuries into Phase IIa trials in Australia.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments